Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 16/20 | 0.72 |
| ▸ | FNTB | P49356 | 16/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.51 |
| ▸ | PGGT1B | P53609 | 4/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28782663 | 1.00 | FNTA (0.72) | FNTAFNTBCYP3A4PGGT1BCNR1 | |
| SCHEMBL4281997 | 0.91 | FNTA (0.60) | FNTAFNTBCYP3A4PGGT1BCNR1 | |
| SCHEMBL4285788 | 0.91 | FNTA (0.60) | FNTAFNTBCYP3A4PGGT1BCNR1 | |
| SCHEMBL1682751 | 0.90 | FNTA (0.61) | FNTAFNTBCYP3A4PGGT1BCNR1 | |
| SCHEMBL4290048 | 0.89 | FNTA (0.58) | FNTAFNTBCYP3A4PGGT1BCNR1 | |
| SCHEMBL4562525 | 0.84 | FNTA (1.00) | FNTAFNTBCYP3A4PGGT1B | |
| SCHEMBL4562526 | 0.84 | FNTA (1.00) | FNTAFNTBCYP3A4PGGT1B | |
| SCHEMBL4276938 | 0.84 | FNTA (0.61) | FNTAFNTBCYP3A4PGGT1BCNR1 | |
| SCHEMBL4278951 | 0.84 | FNTA (0.55) | FNTAFNTBCYP3A4PGGT1BCNR1 | |
| SCHEMBL4282437 | 0.82 | FNTA (0.51) | FNTAFNTBCYP3A4PGGT1BCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014160729-A1 | COMPOSITION AND METHOD FOR TREATING CANCER | CELLWORKS RESEARCH INDIA PVT. LTD (IN) | 2014-10-02 | — | — | WO | disclosed |
| WO-2010124283-A2 | METHODS AND COMPOSITIONS RELATING TO HEMATOLOGIC MALIGNANCIES | THE JACKSON LABORATORY (US) | 2010-10-28 | — | — | WO | disclosed |
| EP-1635641-B1 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2009-03-25 | — | — | EP | disclosed |
| EP-1463728-B1 | FUSED CYCLIC MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL MYERS SQUIBB CO (US) | 2009-01-14 | — | — | EP | disclosed |
| EP-1503757-B1 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2007-12-19 | — | — | EP | disclosed |
| EP-1255537-B1 | FARNESYL PROTEIN TRANSFERASE INHIBITORS FOR TREATING BREAST CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2006-04-19 | — | — | EP | disclosed |
| US-20030212008-A1 | Farnesyl protein transferase inhibitor combinations with further anti-cancer agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212008-A1 | Farnesyl protein transferase inhibitor combinations with further anti-cancer agents | FNTB, FNTA, GGT1 | FNTA 2/4885FNTB 1/4885CYP3A4 3705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.